Drug
Lanreotide Long-Acting Aqueous Gel clinical trials
- studies test it
- 13
- open now
- 0
- in phase 3
- 6
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
- Phase 3
- 6
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Ipsen (8) · Sheba Medical Center (1) · University Hospital, Ghent (1) · Universitaire Ziekenhuizen KU Leuven (1) · Federico II University (1) · Radboud University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Lanreotide Long-Acting Aqueous Gel is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedPhase 3IpsenNCT04852679Written as Lanreotide autogel
- Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of InfancyCompletedPhase 4Sheba Medical CenterNCT01070758Written as Lanreotide autogel
- Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedPhase 3IpsenNCT00690898Written as Lanreotide autogel 120 mg
- Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgCompletedPhase 2IpsenNCT02651987Written as Lanreotide autogel 120 mg
- Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid SyndromeTerminatedPhase 3IpsenNCT00092287Written as lanreotide Autogel (somatostatin analogue)
- Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETCompletedPhase 2IpsenNCT02231762Written as Lanreotide Autogel 120 mg
- Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionCompletedPhase 2IpsenNCT02275338Written as Lanreotide Autogel
- Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedPhase 4IpsenNCT00701363Written as Lanreotide Autogel 120 mg
- Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedPhase 3IpsenNCT02493517Written as Lanreotide Autogel®
- Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for RectumcarcinomaCompletedPhase 3University Hospital, GhentNCT01372007Written as Lanreotide Autogel 120mg
- Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseaseCompletedPhase 2/3Universitaire Ziekenhuizen KU LeuvenNCT01315795Written as Lanreotide Autogel 90 mg and 120 mg
- Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedPhase 4Federico II UniversityNCT00627796Written as Lanreotide-Autogel 120 mg
- Treatment of the Dumping Syndrome With Lanreotide Autogel®Status unknownPhase 4Radboud University Medical CenterNCT00543179Written as Somatuline (Lanreotide Autogel®)